Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimensTamara Castaño-Bonilla, Pau Montesinos, Joaquín Martínez‐López et al.|Scientific Reports|2021Cited by 25
Quizartinib for Newly Diagnosed <i>FLT3</i> -Internal Tandem Duplication–Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI StudyPau Montesinos, Jorge Labrador, Rebeca Rodríguez‐Veiga et al.|Journal of Clinical Oncology|2025Cited by 13
Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA RegistryJorge Labrador, David Martínez‐Cuadrón, Blanca Boluda et al.|Cancer|2024Cited by 5
Final Results of Quiwi: A Double Blinded, Randomized Pethema Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients with Newly Diagnosed <i>FLT3</i>-ITD Negative AMLPau Montesinos, Jorge Labrador, Rebeca Rodríguez‐Veiga et al.|Blood|2024Cited by 5
Erratum: Quizartinib for Newly Diagnosed <i>FLT3</i> -Internal Tandem Duplication–Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI StudyPau Montesinos, Jorge Labrador, Rebeca Rodríguez‐Veiga et al.|Journal of Clinical Oncology|2025Cited by 1